Preconditioning with death ligands FasL and TNF-α protects the cirrhotic mouse liver against ischaemic injury

被引:21
作者
Jang, J-H [1 ]
Moritz, W. [1 ]
Graf, R. [1 ]
Clavien, P-A [1 ]
机构
[1] Univ Zurich Hosp, Dept Surg, CH-8091 Zurich, Switzerland
关键词
D O I
10.1136/gut.2007.137703
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Ischaemic preconditioning is the preemptive proven strategy to reduce ischaemic injury in the liver, but it can be harmful in the elderly or in patients with liver diseases. Ischaemic preconditioning induces a protective effect via activation of oxidative stress. We hypothesised that Fas ligand and tumour necrosis factor a can induce a similar response. Therefore, we tested if death ligands could mimic ischaemic preconditioning. Methods: Ischaemia was maintained for 60 min in cirrhotic mice. Death ligands were given 40 min before ischaemia. Ischaemic injury was assessed by histology and biochemical assays. To elucidate the mechanism, we used zinc protophorphyrin, an inhibitor of haem oxygenase-1 (HO-1), and gadolinium chloride, an inhibitor of Kupffer cells. Results: Compared with the control group, death ligand preconditioning strongly reduced all markers of injury: serum transaminase levels, necrosis and apoptosis. Preconditioning caused an upregulation of HO-1, predominantly in macrophages. When zinc protophorphyrin or gadolinium chloride was applied prior to preconditioning, the beneficial effect of preconditioning was lost. Conclusion: These results demonstrate that ischaemic preconditioning can be replaced by death ligand preconditioning in the cirrhotic liver to prevent ischaemic injury. The protective mechanism depends on HO-1 induction in macrophages. These results open doors for novel hepato-protective strategies in liver surgery and transplantation.
引用
收藏
页码:492 / 499
页数:8
相关论文
共 38 条
[1]
The E3 ubiquitin ligase itch couples JNK activation to TNFα-induced cell death by inducing c-FLIPL turnover [J].
Chang, LF ;
Kamata, H ;
Solinas, G ;
Luo, JL ;
Maeda, S ;
Venuprasad, K ;
Liu, YC ;
Karin, M .
CELL, 2006, 124 (03) :601-613
[2]
Protection of the liver during hepatic surgery [J].
Clavien, PA ;
Emond, J ;
Vauthey, JN ;
Belghiti, J ;
Chari, RS ;
Strasberg, SM .
JOURNAL OF GASTROINTESTINAL SURGERY, 2004, 8 (03) :313-327
[3]
A prospective randomized study in 100 consecutive patients undergoing major liver resection with versus without ischemic preconditioning [J].
Clavien, PA ;
Selzner, M ;
Rüdiger, HA ;
Graf, RF ;
Kadry, Z ;
Rousson, V ;
Jochum, WF .
ANNALS OF SURGERY, 2003, 238 (06) :843-850
[4]
Interferon - The magic bullet to prevent hepatocellular carcinoma recurrence after resection? [J].
Clavien, Pierre-A. .
ANNALS OF SURGERY, 2007, 245 (06) :843-845
[5]
Medical progress: Strategies for safer liver surgery and partial liver transplantation [J].
Clavien, Pierre-Alain ;
Petrowsky, Henrik ;
DeOliveira, Michelle L. ;
Graf, Rolf .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (15) :1545-1559
[6]
Vascular occlusion to decrease blood loss during hepatic resection [J].
Dixon, E ;
Vollmer, CM ;
Bathe, OF ;
Sutherland, F .
AMERICAN JOURNAL OF SURGERY, 2005, 190 (01) :75-86
[7]
Risk factors for hepatocellular carcinoma in HCV-cirrhosis: What we know and what is missing [J].
Fattovich, Giovanna ;
Llovet, Josep M. .
JOURNAL OF HEPATOLOGY, 2006, 44 (06) :1013-1016
[8]
Improving outcome in patients undergoing liver surgery [J].
Furrer, Katarzyna ;
DeOliveira, Michelle Lucinda ;
Graf, Rolf ;
Clavien, Pierre-Alain .
LIVER INTERNATIONAL, 2007, 27 (01) :26-39
[9]
Hepatocellular carcinoma and cirrhosis - Results of surgical treatment in a European series [J].
Fuster, J ;
GarciaValdecasas, JC ;
Grande, L ;
Tabet, J ;
Bruix, J ;
Anglada, T ;
Taura, P ;
Lacy, AM ;
Gonzalez, X ;
Vilana, R ;
Bru, C ;
Sole, M ;
Visa, J .
ANNALS OF SURGERY, 1996, 223 (03) :297-302
[10]
INVOLVEMENT OF THE CD95 (APO-1/FAS) RECEPTOR AND LIGAND IN LIVER-DAMAGE [J].
GALLE, PR ;
HOFMANN, WJ ;
WALCZAK, H ;
SCHALLER, H ;
OTTO, G ;
STREMMEL, W ;
KRAMMER, PH ;
RUNKELL, L .
JOURNAL OF EXPERIMENTAL MEDICINE, 1995, 182 (05) :1223-1230